Q&A: Perspectum to evaluate imaging device as tool to identify NASH patients

Perspectum announced it will evaluate the use of LiverMultiScan as a diagnostic tool to identify eligible patients for enrollment into nonalcoholic steatohepatitis clinical trials.The Virginia Commonwealth University, University of Virginia, Mount Sinai, and Liver Centers of Texas will collaborate in conducting the Non-Invasive Quantification of Liver Health in NASH (N-QUAN) trial as part of the evaluation. This prospective trial will include 225 patients with suspected NASH.Healio Gastroenterology spoke with Andrea Dennis, PhD, head of biomarker sciences at Perspectum, to discuss the trialRead More

Share on facebook
Share on twitter
Share on linkedin